Duke-NUS And Japan-Based Ipgaia Announce Partnership To Accelerate Innovation In Drug Discovery menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.
(0)
Supporting R&D optimization of next-generation biopharmaceuticals with digital technology and drug discovery platform
TOKYO, Apr 7, 2021 - (JCN Newswire) - Hitachi, Ltd. (TSE:6501) and Axcelead, Inc. today announced that they have agreed on a comprehensive collaborative partnership to develop solutions contributing on more efficient creation of next-generation biopharmaceuticals with digital technology and drug discovery platform. Hitachi has also made investment to Drug Discovery Gateway Fund ( DDG Fund ) managed by Whiz Partners Inc. (President: Atsushi Matsumura, Whiz ). Axcelead is the flagship portfolio company of DDG Fund.
With continuous progress of life science, practical applications of next-generation biopharmaceuticals with new therapeutics modalities(1) demonstrating better balance of efficacy and side-effect, such as genes-, cell-, and mRNA(2)- therapeutics, have been recognized. Those new drug discovery modalities are also contributing to the speedy and variety
Hitachi and Axcelead to start joint development of solutions for the efficient creation of next-generation biopharmaceuticals jcnnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jcnnewswire.com Daily Mail and Mail on Sunday newspapers.